Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 3116Neoplasms 2459Carcinoma, Non-Small-Cell Lung 1858Prostatic Neoplasms 1623Colorectal Neoplasms 1401Lung Neoplasms 1293Multiple Myeloma 930Neoplasm Metastasis 919Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 853Ovarian Neoplasms 800Melanoma 782Carcinoma, Hepatocellular 733Stomach Neoplasms 647Squamous Cell Carcinoma of Head and Neck 635Recurrence 635Brain Neoplasms 624Head and Neck Neoplasms 598Glioblastoma 558Lymphoma 549Uterine Cervical Neoplasms 535Triple Negative Breast Neoplasms 511Precursor Cell Lymphoblastic Leukemia-Lymphoma 509Carcinoma, Renal Cell 501Hematologic Neoplasms 464Urinary Bladder Neoplasms 460Endometrial Neoplasms 457Colonic Neoplasms 445Sarcoma 433Lymphoma, Non-Hodgkin 432

Interventions

durvalumab 2Gemcitabine 2titanium silicide 1regorafenib 1pembrolizumab 1Nivolumab 1Injections 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced Biliary Tract Cancer × 1 year × Clear all
NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
604 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT04781192 2026-01-23

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

University of Kansas Medical Center

Phase 1/2 Active not recruiting
40 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT04172402 2025-07-22

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

National Health Research Institutes, Taiwan

Phase 2 Completed
48 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT06978114 2025-07-02

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
46 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡